^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug:BAL3833 (Src kinase inhibitor, pan-RAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Ann Oncol
    Title:

    The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

    Published date:
    10/28/2020
    Excerpt:
    New drug CCT3833 elicits significant preclinical therapeutic efficacy in KRAS-mutant colorectal, lung and pancreatic tumor xenografts…CCT3833 inhibits KRAS-mutant cancer cell growth...CCT3833 is active against a panel of KRAS-mutant PDAC, CRC and NSCLC cell lines...CT3833 has been evaluated in a phase I clinical trial (NCT02437227) and we report here that it significantly prolongs progression-free survival of a patient with a G12VKRAS spindle cell sarcoma.
    DOI:
    10.1016/j.annonc.2020.10.483